JAC Advance Access originally published online on February 3, 2006
Journal of Antimicrobial Chemotherapy 2006 57(4):628-638; doi:10.1093/jac/dki491
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Cohrane Library, reproduced with permission.
Systematic review |
Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials
1 Infection Management Services, Princess Alexandra Hospital, Brisbane, Queensland 4102, Australia; 2 Department of Medicine, University of Sydney, Sydney, NSW 2006, Australia; 3 School of Public Health, University of Sydney, Sydney, NSW 2006, Australia; 4 Cochrane Renal Group, Centre for Kidney Research, Children's Hospital at Westmead, NSW 2145, Australia; 5 Centre for Infectious Diseases and Microbiology, University of Sydney (Western Clinical School), Westmead, NSW 2145, Australia
Received 8 November 2005; returned 1 December 2005; revised 12 December 2005; accepted 15 December 2005
* Correspondence address. Infection Management Services, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Queensland 4102, Australia. Tel: +61-7-3240-2329; Fax: +61-7-3240-5540; E-mail: geoffrey_playford{at}health.qld.gov.au
Objectives: This study aims to systematically identify and summarize the effects of antifungal prophylaxis in non-neutropenic critically ill adult patients on all-cause mortality and the incidence of invasive fungal infections.
Methods: Systematic review and meta-analysis of randomized controlled trials in all languages comparing the prophylactic use of any antifungal agent or regimen with placebo, no antifungal or another antifungal agent or regimen in non-neutropenic critically ill adult patients. We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 3, 2005), MEDLINE (1966 to 2 September 2005) and EMBASE (1980 to week 36, 2005). We also hand-searched reference lists, abstracts of conference proceedings and scientific meetings (1998–2004) and contacted authors of included studies and pharmaceutical manufacturers. The primary outcomes assessed were all-cause mortality and proven invasive fungal infections. Two reviewers independently applied selection criteria, performed quality assessment and extracted data using an intention-to-treat approach. Data were synthesized using the random effects model and expressed as relative risk with 95% confidence intervals.
Results: Twelve unique trials (eight comparing fluconazole and four ketoconazole with no antifungal or a non-absorbable agent) involving 1606 randomized patients were included. For both outcomes of total mortality and invasive fungal infections, almost all trials of fluconazole and ketoconazole separately showed a non-significant risk reduction with prophylaxis. When combined, fluconazole/ketoconazole reduced total mortality by one-quarter (relative risk 0.76, 95% confidence interval 0.59–0.97) and invasive fungal infections by about one-half (relative risk 0.46, 95% confidence interval 0.31–0.68). No significant increase in the incidence of infection or colonization with the azole-resistant fungal pathogens Candida glabrata or Candida krusei was demonstrated, although the confidence intervals of the summary effect measures were wide. Adverse effects requiring treatment discontinuation were not more common amongst patients receiving prophylaxis. Results across all trials were homogeneous despite considerable heterogeneity in clinical and methodological characteristics.
Conclusions: Prophylaxis with fluconazole or ketoconazole in critically ill patients reduces invasive fungal infections by one-half and total mortality by one-quarter. Although no significant increase in azole-resistant Candida species associated with prophylaxis was demonstrated, trials were not powered to exclude such an effect. In patients at increased risk of invasive fungal infections, antifungal prophylaxis with fluconazole should be considered.
Keywords: mycoses , candidiasis , fungaemia , antifungals , fluconazole , ketoconazole , intensive care , critical care
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Bassetti, F. Ansaldi, L. Nicolini, E. Malfatto, M. P. Molinari, M. Mussap, B. Rebesco, F. Bobbio Pallavicini, G. Icardi, and C. Viscoli Incidence of candidaemia and relationship with fluconazole use in an intensive care unit J. Antimicrob. Chemother., September 1, 2009; 64(3): 625 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gafter-Gvili, L. Vidal, E. Goldberg, L. Leibovici, and M. Paul Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Mayo Clin. Proc., September 1, 2008; 83(9): 1011 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Manzoni, I. Stolfi, L. Pugni, L. Decembrino, C. Magnani, G. Vetrano, E. Tridapalli, G. Corona, C. Giovannozzi, D. Farina, et al. A Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates N. Engl. J. Med., June 14, 2007; 356(24): 2483 - 2495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller and D. J. Diekema Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163. [Abstract] [Full Text] [PDF]
|
|